Paraquat claim: what to ask and what to do

What is happening in the paraquat cases?

June 2026 orders set tasks for some cases. A September order skipped one planned meeting. These orders do not mean all cases are over or that you get paid.

Judge Nancy J. Rosenstengel's June 3 order selected nineteen cases from people who had declined offers for limited discovery. It also acknowledged settlement offers that were declined. That is a bounded court record about those claims, not an offer grid for everyone with Parkinson's disease.

The June 10 order dismissed twenty-seven named cases without prejudice over failure to comply with a questionnaire requirement. It did not dismiss the whole federal group or decide the medical cause of every illness. Ask your lawyer whether any order names your case and what response is required.

The September 11 text order canceled a scheduled September 15 conference after progress was reported, while the special master continued work. Do not turn that scheduling change into a claim that all cases settled. Ask for the latest document that actually applies to your filed case or new inquiry.

What does a paraquat lawyer cost?

Request the proposed written fee and expense agreement. Ask whether first contact costs anything. Check what you might owe if there is no payment before you sign.

The ABA model rule says a fee tied to an outcome should explain percentages and expenses. It does not verify a particular firm's price. Ask the lawyer to identify the state rules and the agreement that would govern your claim.

For an exposure claim, ask how the firm would obtain work records, application information and medical expert review. Ask who pays those expenses while the case proceeds. Find out whether costs are taken out before or after the fee and what happens if the claim loses.

Ask whether the first discussion is only an assessment or an offer of representation. Ask who would handle your file and whether any other firm is involved. Keep the written fee terms so later explanations can be checked against the agreement.

What should I do today about exposure?

Had contact with paraquat? Seek medical help right away. For a claim check, keep your work and care records. Do not handle an old chemical container to prove a claim.

EPA warns that contact with paraquat can be serious and says to seek medical assistance immediately. That acute warning is separate from the disputed long-term Parkinson research. It does not require waiting for a diagnosis or a legal inquiry before seeking care.

For a records list, note employers, fields, addresses, years and product labels you can identify safely from existing files. Ask how to obtain application or work records that may clarify an uncertain history. Do not go back to a work site or handle chemicals just to answer an intake question.

Ask your healthcare provider how to request the diagnosis report and related care records. Federal access rules cover specified health records with exceptions. Keep clinical advice with the care team; this page cannot confirm a diagnosis or alter your treatment plan.

What happens after I ask for a paraquat check?

Ask who will review your exposure and medical account. Request a list of missing records and a clear next step. Read the privacy, contact and fee terms before agreeing to share detailed information.

Ask the reviewer to distinguish what you directly remember from what a record or model estimates. A study that used a five-hundred-meter area does not create a legal acceptance radius. Ask why a proposed record matters rather than changing your account to match a study design.

If you already filed, give the lawyer the case number and any questionnaire or order you received. The June dismissal order shows that named court requirements matter for pending files. Sending an inquiry to a website is not proof that a court requirement has been met.

Before sending detailed records, ask which firm receives them, how they are stored and shared, and whether you are agreeing to representation. Ask how to correct an error and when to expect a reply. Confirm the terms with the provider rather than inferring them from a research citation.

Sources and limits of the record check

The linked studies, EPA page and signed court orders have stated dates and limits. A later order or data review may change the record relevant to you. Ask for the source behind any specific legal or medical advice.

Parkinson’s Disease

Parkinson’s disease is a progressive neurodegenerative disorder characterized by the loss of dopamine-producing neurons in the substantia nigra pars compacta of the brain. The disease produces four cardinal motor symptoms: resting tremor (involuntary shaking, typically beginning in one hand), rigidity (stiffness of the limbs and trunk), bradykinesia (slowness of movement and difficulty initiating voluntary movement), and postural instability (impaired balance and coordination). Beyond motor symptoms, Parkinson’s disease causes a range of non-motor symptoms including cognitive decline progressing to dementia in many patients, depression, anxiety, sleep disturbances, autonomic dysfunction, and anosmia (loss of smell). The disease is progressive and currently incurable, with symptoms worsening over time despite treatment.

Resting Tremor

Involuntary rhythmic shaking, typically beginning in one hand ("pill-rolling" tremor) and eventually affecting both sides of the body. The tremor is most prominent at rest and may diminish during voluntary movement. It is often the first noticeable symptom and progressively worsens over time.

Rigidity

Increased resistance to passive movement in the limbs, neck, and trunk. Rigidity causes stiffness, reduced range of motion, and muscle pain. It contributes to the characteristic stooped posture and shuffling gait of advanced Parkinson’s disease.

Bradykinesia

Progressive slowness of movement and difficulty initiating voluntary motor actions. Bradykinesia affects activities of daily living including walking, dressing, eating, and writing. Handwriting becomes progressively smaller (micrographia). Facial expression diminishes ("masked face"). Bradykinesia is the most disabling motor symptom for many patients.

Postural Instability

Impaired balance and coordination that increases the risk of falls. Postural instability typically develops in later stages of the disease and is a leading cause of injury and disability in Parkinson’s patients. Falls frequently result in hip fractures and head injuries.

Cognitive Decline and Dementia

Approximately 50–80% of Parkinson’s patients eventually develop cognitive impairment, and 30–40% progress to Parkinson’s disease dementia. Cognitive symptoms include difficulty with executive function, attention, memory retrieval, and visuospatial processing. Dementia significantly increases the need for full-time care.

Depression and Anxiety

Depression affects approximately 40–50% of Parkinson’s patients and may precede motor symptoms by years. Anxiety affects 30–40% of patients. These neuropsychiatric symptoms result from the same dopaminergic neuron loss that causes motor symptoms and significantly reduce quality of life.

• Paraquat exposure (2.5x increased risk per FAME study)
• Occupational pesticide exposure (farming, agricultural work, pesticide application)
• Rural residential proximity to agricultural pesticide application sites
• Family history of Parkinson’s disease (genetic predisposition compounded by environmental exposure)
• Age over 60 (incidence increases sharply with age, though paraquat can cause early-onset cases)
• Male sex (Parkinson’s disease is approximately 1.5x more common in men)
• History of head trauma
• Exposure to other neurotoxic pesticides (rotenone, maneb, dieldrin)
• Clinical neurological examination: A neurologist evaluates motor function including gait, balance, tremor, rigidity, and bradykinesia using standardized assessment scales (Unified Parkinson’s Disease Rating Scale — UPDRS)
• Medical history and exposure assessment: Detailed history of symptoms, progression timeline, occupational history, residential history, and any exposure to pesticides, herbicides, or other neurotoxic chemicals
• Response to levodopa: A positive response to levodopa/carbidopa medication (the gold standard treatment for Parkinson’s) supports the clinical diagnosis, as the drug replaces the dopamine no longer produced by damaged neurons
• DaTscan imaging: A specialized SPECT scan using ioflupane I-123 that visualizes dopamine transporter density in the striatum, providing objective evidence of dopaminergic neuron loss
• MRI of the brain: Used primarily to rule out other conditions (stroke, normal pressure hydrocephalus, tumors) that can mimic Parkinson’s symptoms
• Neuropsychological testing: Assessment of cognitive function, executive function, memory, and mood to evaluate non-motor symptoms and screen for Parkinson’s disease dementia
• Levodopa/carbidopa (Sinemet) — the gold standard medication that replaces depleted dopamine; most effective treatment for motor symptoms but effectiveness decreases over time and causes motor fluctuations (on-off phenomenon) and dyskinesias after years of use
• Dopamine agonists (pramipexole, ropinirole, rotigotine) — medications that directly stimulate dopamine receptors; used as initial therapy in younger patients or as adjuncts to levodopa
• MAO-B inhibitors (selegiline, rasagiline, safinamide) — medications that slow dopamine breakdown in the brain; used as early monotherapy or as adjuncts to levodopa
• Deep brain stimulation (DBS) — surgical implantation of electrodes in the subthalamic nucleus or globus pallidus; reserved for patients with advanced disease and motor fluctuations not adequately controlled by medication
• Physical therapy and exercise — structured exercise programs including resistance training, balance training, and gait rehabilitation; shown to slow symptom progression and improve quality of life
• Speech therapy and occupational therapy — address voice and swallowing difficulties (hypophonia, dysphagia) and assist with adaptive strategies for daily living activities

Parkinson’s disease is progressive and currently incurable. The rate of progression varies significantly among patients, but the general trajectory is one of increasing motor disability, cognitive decline, and loss of independence over 10 to 20 years. Medication (primarily levodopa) effectively manages motor symptoms for several years, but its effectiveness diminishes over time, and long-term use produces motor complications including on-off fluctuations and involuntary movements (dyskinesias). Deep brain stimulation can provide relief for patients with advanced disease. Parkinson’s disease dementia develops in 30–40% of patients and is associated with significantly reduced survival and quality of life. The disease reduces average life expectancy by 2 to 5 years, with aspiration pneumonia and fall-related injuries as leading causes of death.

• https://www.michaeljfox.org — Michael J. Fox Foundation for Parkinson’s Research
• https://www.parkinson.org — Parkinson’s Foundation (helpline: 1-800-4PD-INFO)
• https://www.ninds.nih.gov/health-information/disorders/parkinsons-disease — NIH National Institute of Neurological Disorders and Stroke
• https://www.apdaparkinson.org — American Parkinson Disease Association

How Litigation Is Impacting Paraquat Manufacturers

The paraquat Parkinson’s litigation has imposed significant financial, legal, and reputational costs on the companies responsible for manufacturing, distributing, and selling paraquat in the United States. Syngenta, as the primary manufacturer, bears the greatest exposure, but Chevron Phillips Chemical and Growmark face substantial liability as major distributors who marketed paraquat to agricultural users without adequate warnings about neurological risks.

Global Regulatory Bans and Corporate Accountability

Syngenta and its predecessors have faced escalating regulatory action, international bans, and litigation for their role in marketing a herbicide linked to Parkinson’s disease while suppressing evidence of its neurotoxicity.

• EU banned paraquat in 2007 after reviewing evidence of neurotoxicity and finding unacceptable risk to operators and bystanders
• Internal "Scientific Influencing Strategy" documents (2003) revealed deliberate efforts to suppress and discredit independent research linking paraquat to Parkinson’s disease
• Syngenta targeted Dr. Deborah Cory-Slechta to keep her off EPA advisory panels and hired v-Fluence reputation management firm to monitor scientific discourse
• Dr. Ray Dorsey’s 2023 agnotology paper systematically documented Syngenta’s campaign to manufacture doubt about the paraquat-Parkinson’s connection, drawing parallels to Big Tobacco

A June 3, 2026 MDL order acknowledged that some plaintiffs declined settlement offers.

Paraquat Parkinson’s Filing Deadlines

Every state has a statute of limitations — a legal deadline — for filing a paraquat Parkinson’s lawsuit. Whether that time has passed depends on your facts, so don't rule yourself out. A lawyer can tell you. Because Parkinson’s disease develops 10 to 20 or more years after paraquat exposure, most states apply a "discovery rule" that is critical to understanding your filing window.

The Discovery Rule: When Does the Clock Start?

Parkinson’s disease does not appear immediately after paraquat exposure — it develops over a latency period of 10 to 20 or more years. Most states apply a discovery rule that starts the statute of limitations when you discovered — or reasonably should have discovered — that your Parkinson’s disease was caused by paraquat exposure. For many plaintiffs, this moment came when media coverage of the litigation, a doctor’s opinion linking their diagnosis to pesticide exposure, or information from the MDL proceedings alerted them to the connection. The discovery rule is particularly important in paraquat cases because many plaintiffs were never warned that paraquat could cause neurological disease.

A retired farmer diagnosed with Parkinson’s in 2020 learns from a television advertisement in 2024 that his decades of paraquat use may have caused his disease

In most states, the statute of limitations starts in 2024 when the farmer first learned of the potential causal connection between paraquat and his Parkinson’s — not when he was diagnosed and not when he last used paraquat decades earlier.

A farmworker’s wife diagnosed with Parkinson’s in 2022 discovers through the MDL proceedings that her exposure came from laundering her husband’s paraquat-contaminated clothing for 15 years

The discovery of the take-home exposure pathway — combined with learning that paraquat causes Parkinson’s — triggers the discovery rule. The clock starts when she learned of both the exposure and the causal connection.

A rural Iowa resident diagnosed with early-onset Parkinson’s at age 52 in 2023 is told by his neurologist that pesticide exposure is a likely contributing factor, and he lived adjacent to paraquat-treated cornfields for 30 years

The neurologist’s medical opinion linking the diagnosis to pesticide exposure may serve as the discovery date, starting the statute of limitations clock from that point.

An April 8, 2026 court order says co-lead counsel and defendants signed a master settlement agreement for certain paraquat claims on September 3, 2025, and a June 3, 2026 court order acknowledged that some plaintiffs declined settlement offers. MDL 3004 listed 6,602 pending actions on October 1, 2026. Whether your filing deadline has passed depends on your facts, so don't rule yourself out. A lawyer can tell you.

This table provides general guidance. Actual deadlines depend on your specific circumstances, including when you discovered the connection between your paraquat exposure and your Parkinson’s diagnosis. An attorney can determine your exact deadline based on the facts of your case and the applicable state law.